A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer
ACTRN 12622001003763 Brief Summary Elevated lipids called ceramides are associated with poorer…
Read more arrow_forward